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Abstract 
This monograph reviews the discovery and development of the cyclin-
dependent kinase inhibitor roscovitine (R-roscovitine, CYC202, 
Seliciclib). The authors summarise the in vitro and in vivo data that have 
formed the basis for clinical investigation of Seliciclib as an anti-cancer 
drug. Kinase selectivity, cellular effects and the pharmacological 
properties of the drug are discussed in addition to the clinical results of 
Seliciclib being reviewed. Novel results on the effect of the drug in 
cardiac hypertrophy are summarized and potential applications of 
Seliciclib in other therapeutic areas, including, inflammation, virology, 
glomerulonephritis and polycystic kidney disease, are discussed. Finally 
the authors argue that optimisation of the therapeutic effect of kinase 
inhibitors such as Seliciclib can be enhanced using a systems biology 
approach involving mathematical modelling of the molecular pathways 
regulating cell growth and division. 
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1. Introduction 
 
Dysregulation of the cell cycle often results in diseases that are leading 
cause of mortality and morbidity in the world. Experimental research into 
cell cycle biology has revealed that progression of the cell cycle is 
regulated by cyclin-dependent kinases (CDKs) which are activated by 
cyclins and inhibited by CDK inhibitors. The cell cycle checkpoints are 
regulated by the CDKs which combine both the mitogenic and growth 
inhibitory signals that are responsible for the cell cycle transitions [1]. 
Dysregulation of CDKs has been associated with several malignancies, 
neurodegenerative disorders, viral and protozoa infections, 
glomerulonephritis and inflammatory diseases.Cyclin-dependent kinase 
inhibitors have been recognized as a new class of compounds and 
introduced as treatment for several diseases, including cancer. This 
monograph discusses the biological properties and clinical applications of 
roscovitine – a synthetic tri-substituted purine that selectively inhibits 
CDK1, 2, 5, 7 and 9. In order to fully understand the mechanism of action 
of roscovitine we first describe the main CDKs, their functions, regulation 
and importance as drug targets for therapeutic intervention. 
 
1.1. Cyclin-dependent kinases, functions, regulation and 
involvement in diseases 
 
Cyclin-dependent kinases area family of serine or threonine protein 
kinases. Members of this family share the common characteristic of 
requiring the binding of a regulatory cyclin subunit for enzymatic 
activation, and may also require the phosphorylation of a threonine residue 
near the kinase active site for full enzymatic activity. They were originally 
identified as proteins that controlled cell cycle events but have also been 
discovered to be involved in other cellular processes. Animal cells contain 
at least thirteen CDKs, only four of which are directly involved in cell 
cycle control, namely CDK1, CDK2, CDK4 and CDK6. CDK7 and CDK9 
are involved in cell growth and the others are involved in the control of 
CDK activity, nerve cell differentiation and the level of basal gene 
transcription (Table 1). 
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Table 1. Known cyclin-dependent kinases, their cyclin partners, and 
biological function(s). 
 
 
Similar to other protein kinases, CDKs have a bi-lobed structure, and can 
undergo two conformational changes that inactivate the enzyme, should 
the partner cyclin be absent. These conformational changes were 
discovered through crystallographic studies on human CDK2. Firstly, a 
flexible loop present at the carboxyl- terminal lobe, called the T-loop or 
the activation loop, blocks the binding of protein substrates at the opening 
of the active site cleft. Secondly, in inactive CDKs, some catalytically 
important amino acid side chains are in conformations that do not allow 
efficient phosphate transfer. Upon cyclin binding two alpha helices induce 
conformational changes in the kinase that allow efficient catalysis. The 
CDK Cyclin partner Biological function 
CDK1 Cyclin A, B G2 and M phase, 
CDK2 Cyclin A, B, E G1,S and M phase, apoptosis, transcription 
CDK3 Cyclin C, E G0 and G1 phase 
CDK4 Cyclins D1, D2, D3 G1 phase, cell differentiation 
CDK5 Cyclins D1, D3, p35, p37 Transcription,  DNA damage response 
CDK6 Cyclins D1, D2, D3 G1 phase 
CDK7 Cyclin H CDK-activating kinase, transcription, DNA repair 
CDK8 Cyclin C Transcription 
CDK9 Cyclins T1, T2a, T2b, K 
Transcription, cell growth, cell 
differentiation, apoptosis 
CDK10 ? ? 
CDK11 Cyclin L ? 
CDK12 Cyclin L ? 
CDK13 Cyclin L ? 
? Cyclin F ? 
? Cyclin G ? 
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PSTAIRE helix reorients the residues that interact with the phosphates of 
ATP and the L12 helix reconfigures the residues of the T-loop and the 
active site. A brief description of the main CDKs is given below. 
 
CDK1 
CDK1 also known as the mitotic kinase [2] is the prototypic cyclin-
dependent kinase. After its identification in fission yeast it was initially 
known as cdc2. It has a length of 297 amino acids and a corresponding 
molecular weight of 34 kDa. The human gene is located on chromosome 
10 at 10q21. The designation cdc2 (cell division control molecule 2) is 
used for cell division control genes and proteins [3]. CDK1 activity is 
modulated by phosphorylation at both stimulatory and inhibitory sites. 
CDK1 kinase activity is stimulated by phosphorylation on Threonine 161 
and is inhibited, should the enzyme be phorphorylated at Tyrosine 15 
(Y15) and Threonine 14 (T14), at the active site of the kinase. These 
residues in CDK1 (Y15 and T14) are substrates for protein kinases, such 
as wee1, mik1 and myt1 and their phosphorylation inhibits the entry of the 
cell into the G2 phase of the cell cycle[4]. Overexpression of Cyclin B1 
and hyper-activation of CDK1 have both been observed in several tumors, 
including breast-, colon- and prostate carcinoma [5]. 
 
CDK2 
CDK consists of298 amino acids in length as has a molecular weight of 
33.9 kDa. The human CDK2 gene is located on Chromosome 12 at 12q13. 
The protein kinase is found in complex with its regulatory partners Cyclin 
E or Cyclin A. Cyclin E is necessary for the transition from phase G1 to S 
and the initiation of the S phase of the cell cycle while Cyclin A is 
required to progress through the S phase.CDK2 is regulated by its protein 
phosphorylation and by the inhibitors p21Cip1 and p27Kip1. Intriguingly, 
despite the key role of CDK2 in cell cycle regulation and the profound 
effects of CDK2 inhibitory compounds on cell fate, it has been reported 
also that CDK2 knockout mice are viable [6]. However, studies with 
melanocytes demonstrate that they are uniquely dependent on CDK2 for 
proliferation [7]. In addition, CDK2 small-molecule inhibitors may have 
different cellular phenotypes compared with cells that have lost expression 
of CDK2.Inactivation of Cip/Kip inhibitors and overexpression of Cyclin 
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E and/or Cyclin A leads to deregulation of CDK2 in various malignancies, 
including melanoma, ovarian carcinoma, lung carcinoma and 
osteosarcoma [5]. 
 
CDK4  
CDK4 is found complexed with Cyclin D and this complex is essential for 
the progression of cells through the G1 phase of the cell cycle. The protein 
consists of 303 amino acids and has a molecular weight of 34 kDa. The 
human CGK4 gene is located on Chromosome 12 at position 12q14. 
CDK4/Cyclin D is one of the kinases that phosphorylate the 
retinoblastoma protein family (Rb), which leads to dissociation of the 
pRb-E2F complex and activation of the transcription of genes required for 
the entry into the S phase. Mutations in the CDK4gene were all found to 
be associated with tumorigenesis. 
 
CDK5 
CDK5 interacts with D1 and D3-type cyclins. The protein shows kinase 
activity only after interaction and activation by CDK5R1 (p35) or 
CDK5R2 (p39). Although p35 and p39 lack cyclin sequence homology, 
crystal structures show that p35 folds in a similar way as the 
cyclins.CDK5 has been found to modulate the metastatic potential of some 
malignancies, including breast and prostate carcinomas[8,9]. This kinase 
has been found to play an essential role in the central and peripheral 
nervous system [10].CDK5 has also been reported to regulate the 
cytoarchitecture of the developing brain [11] and to mediate the neuronal 
migration in post mitotic neurons. CDK5 also has several vital functions 
in neuronal cytoskeleton dynamics, synaptic plasticity [12], drug addiction 
[13], synaptic endocytosis [14] and neurotransmitter release [15]. Thus, 
CDK5 may be involved in the pathogenesis of several neurodegenerative 
disorders, such as Alzheimer’s and Parkinson’s diseases [10]. 
 
CDK6  
CDK6 has a size of 326 amino acids, a molecular weight of 40 kDa and 
the human CDK6 gene is located on chromosome 7 at position 7q21-22. 
Together with CDK4, CDK6 is known as G1-phase CDK and binds to 
Cyclin Ds, to form CDK6/Cyclin D complexes. The activity of thiskinase 
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plays a significant role in the progression of cells through the G1 phase of 
the cell cycle [16]. The two kinases, CDK4 and CDK6, share 71% identity 
at the amino acid level and both can bind in vitro with all 3 type-D cyclins 
to phosphorylate pRb [17–21]. CDK4 and CDK6 double knockout-mice 
die during development due to anemia, an observation which taken 
together with the mild phenotype exhibited by CDK6 knockout-mice, 
whose only defects are also haematopoietic, points toward a role for the 
two kinases in haematopoiesis, and at least some redundancy in function 
between the two [22]. 
 
The two kinases have shown differing substrate specificities in vitro– with 
CDK4 phosphorylating Thr-826 of pRb, while CDK6 targets Thr-821 – a 
result which also suggests that the CDK alone can direct substrate 
recognition [23]. Expression studies in a variety of tumour and cell types 
have also shown differential expression and localisation of the two 
kinases. Mutations in the binding site of the CDK4 inhibitor p16INK4A have 
been discovered in cases of familial melanoma [24]; and in squamous cell 
carcinomas and neuroblastomas CDK6 has been found to be 
overexpressed, with CDK4 expression unchanged [25, 26]. In T cells 
CDK6 has been detected in both nuclear and cytoplasmic fractions; 
however, any pRB phosphorylating activity was limited to the nuclear 
fraction, indicating the possibility for differential kinase or inhibition 
activation across cellular compartments [27]. 
 
CDK6 activity has been implicated in the inhibition of differentiation 
across a number of cell types. In murine erythroid leukaemia cells 
inhibition of CDK6 has been shown to induce terminal differentiation 
while inhibition of CDK4 did not have this effect [28]. Osteoblast 
differentiation has also been shown to be inhibited by expression of 
CDK6, and this effect was said to be independent of any role in the control 
of the cell cycle [29]. Interestingly for a kinase, generally considered 
mitogenic, this role in differentiation may be due to CDK6 activity 
reducing rates of cellular proliferation. 
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CDK7 
CDK7 exists as a part of a three protein complex consisting of CDK7, 
Cyclin H and MAT1 (“ménage à trois”) that is also known as Cyclin-
dependent kinase Activating Kinase (CAK) and is responsible for the 
phosphorylating activation of CDKs 1,2,4 and 6. This complex is also, 
along with another six proteins, part of the general transcription factor 
TFIIH, and so is involved in the early pre-initiation and initiation steps of 
transcription. 
 
CAK either does not phosphorylate monomeric CDKs or does so only 
poorly, requiring the presence of the partner cyclin to cause a 
conformational change in the kinase, exposing the activation loop and 
allowing CAK to phosphorylate. Like other CDKs, CDK7 is 
phosphorylated on the activation loop, but this modification is not required 
for enzymatic activity, instead the presence of MAT1 in complex with 
CDK7 and Cyclin H can substitute for the activating phosphorylation. 
 
As a part of TFIIH CAK hyperphosphorylates the C-terminal domain 
(CTD) of the large subunit of RNA polymerase II, thus promoting the 
initiation of transcription, an event that CAK alone is unable to catalyse. 
CAK, as a part of TFIIH, is phosphorylated by CDK1/Cyclin B during 
mitosis – an event that causes the loss of the TFIIH’s CTD’s 
phosphorylating activity, and is at least in part responsible for the 
silencing of transcription during mitosis. 
 
Temperature sensitive CDK7 mutants in C. elegans exhibit a block in the 
cell cycle which can be attributed to loss of CAK activity rather than any 
CTD phosphorylating function [30]; and in Drosophila CDK7 mutations 
are lethal and cause death before or during pupation due to mitotic 
catastrophe, similar to mutations in the CDK1 gene suggesting that the 
gene is required for mitotic proliferation [31]. Similarly in mice deletion 
of the MAT1 causes embryonic lethality. In addition, RNAi knockdown of 
MAT1 in rat smooth muscle cells and abrogation of the protein in human 
osteosarcoma cell lines leads to arrest of the cell in the G1 phase of the 
cell cycle, apoptosis in the rat smooth muscle cells, and is associated with 
a reduction in pRb phosphorylation [32, 33]. 
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CDK8 
CDK8 is a 464 amino acid serine-threonine protein kinase with a 
molecular weight of 53.3 kDa whose gene CDK4 is located on 
chromosome 13 at position 13q12. The protein is located in the nucleus 
and along with CDK7 and CDK9 makes up the transcriptional CDKs 
(rCDKs) as they have all been identified as having role(s) in 
transcriptional control. Similar to CDK7 – CDK8 can also phosphorylate 
the C-terminal domain of RNA Polymerase II in vitro;however, its 
specificity is for residues Ser-2 and Ser-5, as opposed to the Ser-5 and 
Ser-7 targeted by CDK7. The cyclin partner for CDK8 is Cyclin C, which 
does not show cell cycle-dependent fluctuations in concentration; control 
of CDK8 activity is modulated rather by other factors, such as association 
with Mediator Complex Subunit 12 (MED12) [34–38]. CDK8 is part of 
the large multi-subunit transcriptional regulatory complex Mediator that 
functions in eukaryotes as a transcriptional co-activator. This 25–30 
member, 1.2MDa complex is required for successful transcription from 
almost every class II promoter, at least in yeast [39]. The complex binds to 
the CTD of RNA Polymerase II and acts as a co-activator of transcription. 
Many members of the complex provide a large and varied surface area for 
protein-protein interactions, thus acting as a scaffold between RNA Pol II 
and transcription factors [40, 41]. 
 
CDK8 has been attributed to oncogenic potential in colon cancer cells due 
to effects observed on the Wnt/β-catenin pathway in cultured cells [42]. 
CDK8 was identified in a shRNA screen as being required for colon 
cancer cell proliferation and Wnt/β-catenin driven signalling. CDK8’s 
copy-number was also shown to be frequently increased in colon cancers, 
suppression of CDK8 expression reduced proliferation of colon cancer 
lines, overexpression of wildtype, but not kinase-dead, CDK8 led to 
transformation of NIH3T3 cells [42, 43]. 
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CDK9 
CDK9 is a 372 amino acid, 42.8 kDa serine-threonine kinase encoded by 
the CDK9 gene on chromosome 9 at position 9q34.1. The kinase has been 
found complexed with two cyclins, Cyclin T and Cyclin K. The kinase 
subunit forms the catalytic core of positive transcription elongation factor 
b (p-TEFb) [44–47]. It plays a crucial role in increasing transcriptional 
elongation from RNA Pol II-dependent promoters, including many key 
developmental and response genes, as well as the vast majority of protein 
coding genes [48]. Activity of CDK9 is controlled by associations with 
other proteins, most notably its cyclin partners, Cyclin T and Cyclin K, but 
also other activatory cellular proteins, such as c-myc, NF-κB, androgen 
receptor; and inhibitory complexes, such as the 7SK small nuclear RNA 
containing complex [49–54]. 
 
          Regulation of CDKs 
Understanding the biological role and the regulation of cyclin-dependent 
kinases is important for selecting drug targets and developing strategies 
for modulating their activity for therapeutic purposes. 
 
CDKs are regulated by several mechanisms, including transcription and 
translation of their subunits, heterodimerization with cyclins, post-
translational modification by phosphorylation and dephosphorylation, and 
interactions with their natural inhibitors.The endogenous CDK inhibitors 
consist of two families, the INK4 family and the KIP (kinase inhibitor 
protein) family[55]. 
 
Members that fit into the INK4 family e.g.: p15INK4B and p16INK4A, inhibit 
CKD4 and CDK6; while members of the KIP family, e.g.: p21Cip1, p27Kip1 
and p57Kip2, have diverse activities [55]. On one hand p21 and p27 
activate formation of CDK/Cyclin D complexes trough increasing stability 
of Cyclin D’s, facilitation of the assembly of these complexes, and 
increasing nuclear localization of CDK/Cyclin D complexes. On the other 
hand they bind to the assembled complex and inhibit its kinase activity. 
The above proteins and peptides derived from them have been widely used 
as tool compounds for studying the regulation of the cell cycle, and can 
have potential therapeutic application. Among the variety of cell cycle 
                                                      Seliciclib - discovery and development 
 
 
 
BioDiscovery                                  10                         December  2013 | Issue 10 | 1 
 
inhibitors that are present, those important in the regulation and control of 
the cell cycle and used as tools for drug development are mentioned 
below. 
 
p16 
p16 is the main member of the INK4 family of inhibitors, which plays key 
role during the G1 and S phases of the cell cycle. The family includes p15, 
p16, p18 and p19 which tend to inactivate only the G1 CDK’s – CDK4 
and CDK6. Prior to their attachment with cyclins, they form stable 
complexes with the CDK’s, and overexpression of cyclins will not 
separate them from the CDK. Due to the binding that occurs between the 
members of the p16 family and CDK4 or CDK6, it does not permit the 
phosphorylation and inactivation of pRb. [4].It is transcribed from the 
9p21 locus and, rather than directing cells towards neoplasia, it may direct 
them towards senescence [56]. P16 is described as a tumour suppressor. 
 
p21 
The proteins of the p21 family are important in the regulation of G1 phase 
of the cell cycle and include waf1 (also called p21), p27 and p57. Except 
for CDK1, they can inhibit most of the CDKs. Due to its binding with 
cyclins, they prevent the CDK from phosphorylating the pRb and unlike 
p16, these induce dissociation from E2F. The role of p21 in oncogenesis is 
still unclear, but it might act as a tumour suppressor since it plays the role 
of an inhibitor during the cell cycle [4]. It is said by Gartel AL et al. [57], 
that p21 is regulated at the transcriptional level, it is an inhibitor of 
apoptosis, and its suppression may have anti-cancerous consequence. Its 
overexpression during the cell cycle may arrest the G1, G2 or the S phase. 
It is said to advance the development of active complexes in a 
concentration dependent manner by stabilising contact between CDK4or 
CDK6 and Cyclin D [57]. 
 
p27 
p27 inhibits cyclin-dependent kinases that help in the regulation of the cell 
cycle through which cells progress. This inhibitor was initially discovered 
in cells that were arrested by transforming growth factor α (TGF-α) or by 
contact inhibition or after treatment with lovastatin. It is found to be in 
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conjugation with CDK/Cyclin D complexes in those cells that proliferate, 
while in those G1 arrested cells it binds itself to CDK2/Cyclin E 
complexes. Hence it is crucial to which complex p27 binds and there 
remains a competition between CDK/Cyclin D and CDK2/Cyclin E 
complexes. If the former can sequester p27 from the latter then it can push 
the cell into the S phase. In the experimental studies related to breast 
cancer, Chiarle et al compared the levels of p27 and the activities of 
CyclinE and Cyclin D1-dependent kinases and found that an inverse 
correlation exists between CyclinE-dependent kinase and p27 [55]. 
 
The activity of p27 seems to increase on loss of adhesion to the 
extracellular matrix, in response to differentiation signals and by the 
signals of TGF-α, a growth inhibitory factor, while mitogenic factors 
cause its loss. [55]. In inactive cells the level of p27 appears high and 
during the G1 phase the levels decrease reaching its lowest phase during 
the S phase. High levels of nuclear p27 protein are seen in most of the 
normal epithelial tissue, including prostate, ovary, lung and breast, 
especially in the terminally differentiated layers. On the contrary, in the 
proliferating cells, such as the basal layer of the epithelia or in the 
germinal centre lymphocytes, the level of p27 seems to be practically 
untraceable [55]. 
 
1.2. CDK inhibitors as potential therapeutics. 
 
As already mentioned CDKs are key regulators of cell cycle and other 
fundamental biological processes, such as transcription. Consequently the 
main effects of CDK inhibitors are induced via modulation of the cell 
cycle progression and inhibition of transcription. 
 
Notably dysregulation of the cell cycle is a common event in 
tumorigenesis and leads to uncontrolled cell proliferation and 
independence from extracellular mitogenic signals. In a normal cell, 
initiation of the cell cycle is achieved through stimulation with growth 
factors. Such mitogenic stimulation results in a cascade of serine-
threonine kinase activities resulting with induction of Cyclin D1 
transcription. Cyclin D1 then binds to CDK4 and CDK6 to give active 
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kinase complexes. The latter directly phosphorylates the retinoblastoma 
protein (Rb), causing dissociation of histone deacetylase 1, allowing 
histone acetylation, which is permissive for transcription. As a result key 
cell cycle regulators, such as Cyclin E are transcribed and translated. 
Cyclin E then forms a complex with CDK2, which further phosphorylates 
Rb with the release of the general transcription factor E2F. E2F stimulates 
the transcription of genes required for progression through to the synthesis 
phase of the cell cycle. 
 
Dysregulation of the cell cycle occur through various mechanisms. They 
include: mutations leading to constitutive activation of the signal 
transduction pathways[58], which results in uncontrolled production of 
Cyclin D; loss, mutation or methylation of p16 – the endogenous inhibitor 
of CDK4/Cyclin D and CDK6/Cyclin D [59]; constitutive activation of 
CDK4 via mutations [60]; viral inactivation of p21 [61] and loss or 
mutations of Rb [62]. All of the above mechanisms override the anti-
proliferative activity of Rb and confer a greater propensity for cells to 
progress through the cell cycle. That is why CDKs involved in cell cycle 
control have been considered as attractive targets to restrict uncontrolled 
cell proliferation. This includes CDKs involved in G1/S transition but also 
CDKs playing role in other phases of the cell cycle, such as CDK2/Cyclin 
A. The latter maintains pRb in its hyper-phosphorylated state allowing 
completion of the S phase of the cell cycle. As the cell exits S phase 
timely neutralisation of E2F transcriptional activity is required, otherwise 
the apoptotic mechanisms are triggered leading to cell death. The 
neutralisation occurs through CDK2/Cyclin A activity to E2F and leads to 
dissociation from the DNA. It is this pathway which is the most promising 
from a CDK inhibitory point of view, since inhibition of CDK activity 
would maintain E2F in its DNA bound state and trigger apoptotic cell 
death. In addition, as discussed above, E2F is commonly deregulated in 
many tumour cell lines, and this overexpression is a viable target for CDK 
inhibition – with the aim of keeping E2F DNA bound into G2, and hence, 
inducing apoptosis. The validity of CDK2/Cyclin A as a drug target in 
tumours with upregulated E2F activity has been proved experimentally – 
using cell-permeable peptides, which block the interaction between Cyclin 
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A and E2F [63–65]. Such peptides kill transformed cells, but not their 
normal counterparts [66]. 
 
In addition to control of the cell cycle, some CDKs are involved in 
regulation of RNA polymerase II-mediated transcription. There are three 
RNA polymerase II (RNAPII) directed cyclin-dependent protein kinases 
which play roles in RNAPII activation. These are CDK7, 8 and 9, and 
they all phosphorylate the serine-rich C-terminal domain (CTD) of 
RNAPII to allow the consecutive attachment of the elongational 
transcription factors. Soon after initiation, CDK7 (the kinase subunit of 
transcription factor TFIIH) phosphorylates Serine 5, causing RNAPII to 
become arrested in the promoter-region due to its interaction with negative 
elongation factors (NELF). Phosphorylated Serine 5 also mediates the 
recruitment of mRNA capping enzymes. After capping, CDK9 
phosphorylates Serine 2 which counteracts the suppressive action by 
NELF and allows RNAPII to advance from the promoter and so allows 
transcriptional elongation [67]. Serine 2 is dephosphorylated by TFIIF-
dependent CTD phosphatase FCP-1 during termination of transcription, 
and the unphosphorylated RNAPII is recycled.CDK8 is suppressive, in 
that it phosphorylates RNAPII preventing it from binding to the promoter, 
and has additional suppressive activity by phosphorylating Cyclin H, thus 
preventing the activation of CDK7. This suggests that CDK8 is a 
suppressor of transcription and CDK7 and in particular CDK9 appear to 
be more attractive as targets for drug development. 
 
Importantly roscovitine inhibits RNAPII-mediated transcription, which 
downregulates the expression of anti-apoptotic proteins, such as Bcl-2, 
Mcl-1, survivin and others [68]. These proteins have short half-lives and 
their transient downregulation can trigger an irreversible activation of 
apoptosis in tumour cells, but not in normal cells, which do not depend on 
survival factors. Notably, myeloma cells treated with small molecule 
inhibitors of CDK9 have an increased level of apoptosis caused by the loss 
of short half-life proteins, such as the anti-apoptotic proteins XIAP and 
Mcl-1, and the proliferative D-type cyclins. These effects have been 
assigned to abrogation of transcription due to inhibition of CDK9 activity, 
although such an absolute assignment is difficult because the small 
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molecule inhibitors used in the studies, including roscovitine, inhibit 
multiple CDKs [69–73]. Various aspects of CDK 9 as a potential drug 
target in virology and inflammation have been reviewed by ourselves 
previously [74]. Here we give a brief overview of the latest insights 
regarding potential application of CDK9 inhibitors in cardiology and in 
particular in heart hypertrophy. 
 
The amount of phosphorylated (active) RNAPII increases rapidly in 
response to hypertrophic stimuli, such as endothelin-1 (ET-1) and 
Angiotensin (Ang) II, due to increased phosphorylation of Ser-2 of the C-
terminal domain–the serine rich region which is preferentially 
phosphorylated by CDK9. CDK9 is, therefore, the essential CTD kinase 
for hypertrophic growth – an observation further reinforced by much 
experimental data, such as that from Sano and Schneider(2004)[75], which 
showed that in vitro CDK9 activity was required for hypertrophy in a 
tissue culture model, and in vivo, in a mouse model,heart-specific activity 
of CDK9 by Cyclin T1 provoked hypertrophy in mice. In addition, they 
found that mutations in CDK9 blocked the effect of hypertrophic stimuli. 
Sano and Schneider(2004)[75] also showed that inhibition of CDK7 had a 
much smaller effect on the increase in size following growth stimuli, 
showing that CDK9 is the RNAPII kinase associated with abnormal 
protein synthesis in pathological cardiac hypertrophy. 
 
Hypertrophic signalling pathways stimulate CDK9 activation by causing 
the dissociation of 7sk (a small nuclear RNA) from CDK9, unleashing 
CDK9 function. 7sk, when bound to CDK9, causes inhibition of the 
catalytic activity. Hypertrophic signals result in the liberation of functional 
P-TEFb (positive transcription elongation factor b) from its endogenous 
inhibitor, which is the CDK9/Cyclin T heterodimer. The following 
diagram (Fig. 1) helps to convey the activation of CDK9 by hypertrophic 
stimuli [75]. 
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Figure 1. Role of CDK 9 in cardiac hypertrophy and as potential target for 
drug development. 
 
CDK9 is also involved in mitochondrial dysfunction, observed as a result 
of cardiac hypertrophy. This dual transcription role of CDK9 in both 
hypertrophic growth and in mitochondrial dysfunction further highlights 
the potential utility of CDK9 as a drug target for the inhibition cardiac 
hypertrophy. Overall, the activity of CDK9 is upregulated in cardiac 
hypertrophy, and consequently, CDK9 inhibition is a potentially attractive 
molecular target for therapeutic intervention in cardiac hypertrophy [75]. 
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2. Discovery of roscovitine 
 
It was in the laboratory of Pierre Guerrier at the Roscoff Biological 
Station that Laurent Meijer, after spells in the labs of Maurice Durchon in 
Lille and David Epel at Stanford, realised that starfish oocytes were 
perhaps the ideal model to study the role of protein phosphorylation in the 
prophase/metaphase transition of the cell cycle [76–79]. Having studied 
the histone phosphorylation associated with this transition before, the 
starfish oocyte had advantages over the previous systems he had worked 
on, namely the ability to isolate the oocytes in large quantity in natural 
seawater. The oocytes are naturally arrested in prophase, but addition of 
the hormone 1-methyladenine induces a rapid and synchronous transition 
to metaphase [80, 81]. 
 
The use of protein phosphates and phosphatase inhibitors had led to the 
initial anecdotal identification of protein phosphorylation as a mechanism 
in the control of the cell cycle [78, 82]. While working with Steven Pelech 
in Edwin Krebs’ laboratory during a sabbatical a histone kinase specific to 
the M-phase was identified that was strongly activated during the 
prophase metaphase transition [83, 84]. Further biochemical studies 
subsequently identified the kinase as a heterodimer of cdc2, the kinase 
subunit, and a regulatory protein–Cyclin B [85–87]. These observations 
taken together with many other studies [88–90] had finally solved the 
riddle of almost twenty years that CDK1/B was the “maturation promoting 
factor” present in all species, the factor that when injected into prophase-
arrested oocytes induced the transition into metaphase. 
 
The central role of CDK1 and its requirement for cell division made it an 
immediate target for scientists interested in identifying potential anti-
cancer agents. A radioactive in vitro kinase assay [87, 90, 91] was 
established with the goal of identifying inhibitors of the kinase. Initial 
tests with then current chemotherapeutic agents were negative, only the 
non-specific kinase inhibitor Staurosporine (Fig. 2) was available as a 
control compound. It was only when the compound 6-
dimethylaminopurine (DMAP) was tested that the first purine based 
kinase inhibitor was discovered (Fig. 2). The compound was initially 
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identified as a Puromycin analogue that, although it no longer inhibited 
protein synthesis, was a potent inhibitor of mitosis in the sea urchin 
embryo [92]. During work on the M-phase specific phosphorylation it had 
been observed that DMAP was a potent inhibitor of this event, raising the 
possibility, subsequently proven using in vitro kinase assays, that DMAP 
was an inhibitor of the maturation specific factor – CDK1/Cyclin B [91, 
93, 94]. DMAP and a related purine, isopentenyladenine (Fig.2)were 
found to be inhibitors of CDK1/Cyclin B, but with IC50 values of 120µM 
and 55µM, respectively, were neither particularly potent nor 
selective.Isopentenyladenine was known to be key intermediate in the 
synthesis of cytokinins, plant hormones involved in many aspects of the 
control of plant cell growth; and this knowledge led to a contact of the 
Biological Station Roscoff scientists with JaroslavVesely and 
MiroslavStrnad at the Institute of Experimental Botany in Olomouc, who 
had a collection of isopentenyladenine analogues and other substituted 
purines. This collaboration led to the identification of 2-(2-
hydroxyethylamino)-6-benzylamino-9-methylpurine, a compound 
subsequently named olomoucine (Fig. 2), as a kinase inhibitor with 
specificity for CDK and MAPK over some 30 other tested kinases [95]. 
This observed kinase specificity was surprising, given that the dogma of 
the time said that ATP-competitive molecules, such as substituted purines, 
would never show specificity given the similarity of these binding sites in 
kinases. Olomoucine was also approximately a lot more potent than 
isopentenyladenine with IC50 values of 7, 7, 7, 3 and 25µM against the 
kinases CDK1/Cyclin B, CDK2/Cyclin A and CDK2/Cyclin E kinases, the 
brain CDK5, and the map-kinase ERK1, respectively.  
 
Further attempts to improve selectivity and potency of these substituted 
purines was carried out in the laboratories of MiroslavStrnad in Olomouc 
(Czech Republic) and Michel Legraverend at the Institute Marie Curie in 
Orsay(France) and resulted in the identification of the 6-(benzylamino)-
2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine (Fig.3), 
subsequently named roscovitine [96], a potent inhibitor of CDK1/Cyclin B 
with an IC50 value of 0.45µM. Subsequent crystallographic structures of 
roscovitine and olomoucine in complex with CDK2 provided the basis for 
a significant amount of structure-guided medicinal chemistry work [97]. 
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Figure 2. Chemical structures of some of the first CDK inhibitors. 
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Figure 3. 2D (A)  and 3D (B) structure of roscovitine. 
 
3. Chemical synthesis and physicochemical properties of 
roscovitine 
 
We have synthesised (R)-roscovitine (CYC202) and its (S)-enantiomer 
[98] and molecular structure of the produced CYC202 was determined 
unambiguously by X-ray diffraction. Briefly, compound 2,6-
dichloropurine (1) was converted into N-benzyl-2-chloro-9H-purin-6-
amine (2) up on heating with benzylamine in the presence of triethylamine 
in n-butanol for a period of 3 hours. Treatment of the intermediate 2 with 
isopropylbromide in the presence of potassium carbonate afforded N-
benzyl-2-chloro-9-isopropyl-9H-purin-6-amine (3) in 85% yield. 
Amination of the latter with excess of (R)-2-aminobutan-1-ol (8 mol 
equiv.) at 160oC for 8 hours, followed by re-crystallisation in ethyl 
acetate, yielded compound CYC202 as white crystalline (Fig. 4). 
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Figure 4. Synthesis of CYC-202 ((R)-Roscovitine). Reagents and conditions: 
(a) benzylamine, BuOH, NEt3, 110oC, 3 h, 95%; (b) 2-bromopropane, 
K2CO3, DMSO, 18-20oC, 5 h, 85%; and (c) (R)-2-aminobutan-1-ol, 160oC, 8 
h, 89%. 
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We have also determined some of the physiochemical properties of 
roscovitine [98], which are summarized in Table 2. 
 
Table 2. Physicochemical properties of roscovitine. 
IUPAC name 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine 
Chemical name 
1-butanol, 2-[[9-(1-methylethyl)-6-
[(phenylmethyl)amino]-9H-purin-2yl]amino], 
(2R)-(R)-2-(6-benzylamino-9-isopropyl-9H-
purin-2-ylamino)-butan-1-ol 
Other names (R)–Roscovitine, (S)-Roscovitine, CYC202, Seliciclib 
Molecular formula C19H26N6O 
State White powder 
Solubility Soluble in DMSO (up to 50 mM) and in 50 mM HCL with the pH adjusted to 2.5 
Atomic composition C= 64.38%; H=7.39%; N=23.71%; O=4.51% 
Molecular weight 354.45 
Rotation values (R)-Roscovitine: [α]D
20+ 56.3, (S)-Roscovitine: 
[α] D
20-56.3 
Melting point 106-108°C 
pKa 4.4 
Absorption λ max 230nm and 292nm 
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4. Inhibition of CDKs by R-roscovitine (CYC202) 
 
De Azevedo et al. (1997) [97] investigated the kinetics of roscovitine 
inhibition of p34cdc2/Cyclin B kinase purified from starfish oocytes, and 
determined the crystal structure of the CDK2- roscovitine complex. 
Roscovitine was shown to be a competitive inhibitor of p34cdc2/Cyclin B 
kinase (Ki=1.2μM). X-ray crystallographic studies demonstrated that the 
purine portion of the roscovitine molecule binds to the adenine binding 
pocket of CDK2. The benzyl ring of the roscovitine molecule forms 
contacts with the CDK2 enzyme that are not observed in the ATP-CDK2 
complex, which provides the basis for the selectivity of roscovitine. The 
interaction involves hydrophobic and van der Waals contacts and three 
hydrogen bonds. Two of them involve atoms N7 and N6 of roscovitine and 
backbone atoms of Leu83 of CDK2. The third hydrogen bond is formed 
between the hydroxyl group of roscovitine and a water molecule, which 
mediates the interaction with CDK2 (Fig. 5). 
 
 
Figure 5. Interactions of (R)-Roscovitine with CDK2.  A - 3D structure  of 
human CDK2 with (R)-Roscovitine. B - (R)-Roscovitine’s atoms involved in 
hydrogen bonds: red arrows -hydrogen donors, green arrow - hydrogen 
acceptor. 
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These studies also revealed that it is the (R)-enantiomer of roscovitine 
which is bound by CDK2 (this enantiomer is about twice as potent as the 
(S)-enantiomer in inhibiting cdc2/Cyclin B). This provides the rationale 
for clinical development of the (R)-enantiomer of roscovitine. 
 
The specificity of roscovitine was demonstrated by Meijer et al. (1997) 
[99] by screening for inhibition against 25 highly purified kinases. The 
above study confirmed that roscovitine has a narrow spectrum of activity 
showing specificity for cdc2/Cyclin B, CDK2/CyclinA, CDK2/CyclinE 
and CDK5/p35 (IC50 values for these enzymes were 0.65, 0.7, 0.7 and 
0.2µM, respectively). The cyclin kinases CDK4/Cyclin D1 and 
CDK6/Cyclin D3 were not significantly inhibited by 
roscovitine(IC50>100µM for both enzymes). It is worth noticing that the 
ATP concentration used in these experiments (15µM) was significantly 
lower than the concentration of ATP in cells (typically more than 1mM). 
We have confirmed that CYC202 (R-roscovitine) is a potent inhibitor of 
recombinant CDK1/CyclinB, CDK2/CyclinA, CDK2/CyclinE and 
CDK7/CyclinH, with IC50 values for these enzymes, respectively: 2.69, 
0.71, 0.1, and 0.49 µM using in vitro kinase assays with 100mM ATP 
[100]. It has also been determined that roscovitine is a potent inhibitor of 
CDK9/CyclinH, although the IC50 values reported varied between 0.79 
[74] and 3.2µM [101]. Notably a large number of kinases (including: 
AMPK, Aurora B, Aurora C, BRSK2, CAMK1, CAMKKα, CAMKKβ, 
CK1δ, CK2, EF2K, IKKβ, Lck, MAPKAP-K2, MAPKAP-K3, MARK3, 
MELK, MKK1, MSK1, MNK1, MNK2, ERK1, MAPK2/ERK2, MARK3, 
NEK2a, NEK6, NEK7, JNK1, JNK2, JNK3, JNK/SAPK1c, SAPK2a/p38, 
SAPK2b/p38, SAPK3/p38, SAPK4/p38, p38α/MAPK, P38β/MAPK, 
p38δ/MAPK, ERK8, MAPKAP-K1a, MAPKAP-K2, MSK1, MST2, 
HIPK2, HIPK3, PAK4, PAK5, PAK6, PIM1, PIM2, PIM3, PLK1, PRAK, 
PRK2, PKA, PKA1, PKCα,PKCζ, PDK1, PKBα, PKBβ,PRAK, RSK1, 
RSK2, SRPK1, SmMLCK, SGK, SGK1, S6K1, Src, GSK3β, ROCK-II, 
AMPK, CHK1, CHK2, CK2, PHK, LCK, CSK, GSK3β, CK1, 
DYRK1A,DYRK2, DYRK3) are poorly, if at all, sensitive to roscovitine 
[102, 103]. 
 
 
                                                      Seliciclib - discovery and development 
 
 
 
BioDiscovery                                  24                         December  2013 | Issue 10 | 1 
 
5. CYC202 inhibits cell growth in vitro 
 
Due to the pivotal role of CDKs in a wide range of cellular functions, 
roscovitine has been suggested as a potential treatment for several diseases 
that involve the cell cycle. The effects of roscovitine have been studied in 
vitro in cell lines and in vivo in animal models. In vitro studies have been 
carried out in more than 100 cell lines, including the NCI-60 cell line 
panel of the national cancer institute (NCI). 
 
Meijer et al. (1997) [99] demonstrated that roscovitine exhibited inhibitory 
activity against human tumour cell lines in vitro, in a study using 60 
different tumour cell lines derived from nine different tumour types. 
Roscovitine was tested at concentrations ranging from 0.01µM to 100µM 
with a 48 hour exposure time. All cell lines displayed a similar sensitivity 
to roscovitine, and the average IC50 was 16µM. The nature of the 
inhibition was further characterised in experiments with the cell line 
L1210, which demonstrated that roscovitine arrested the cells in the G2/M 
phases of the cell cycle. Raynaud et al [104] reported 24 cell lines with an 
average IC50 of 14.6µM. 
 
We have investigated the potential for CYC202 to inhibit the growth of 
cultured tumour cells in vitro using a panel of nineteen different human 
tumour cell lines and three non-proliferating human cell lines [100]. Cell 
growth was determined using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. CYC202 exhibited growth inhibition 
for all cell lines tested, with IC50 values ranging from 7.9µM to 30.2µM. 
In addition, the data demonstrated an average of four-fold selectivity for 
actively dividing tumour cells over normal cells. 
 
We have also studied the minimum length of exposure to CYC202 
required to achieve the maximum growth inhibitory effect using the 
human ovarian cancer cell line A2780, and determined a required 
exposure time of at least 16 hours – a period of time equal to 
approximately one cell cycle for A2780 cell line. Given that these cells are 
asynchronous, it is, therefore, likely that the molecular target must be 
inhibited during the appropriate phase of the cell cycle in order to cause 
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growth arrest in the cells. In addition, we also evaluated the ability of 
CYC202 to induce cell cycle arrest and apoptosis in the human lung 
tumour cell line A549. Information on cell cycle distribution of the cells 
was obtained from DNA content analysis of ethanol-fixed, propidium 
iodide stained, A549 cells following treatment. The major effect observed 
following 24 and 48 hours exposure to 50 or 100μM CYC202 was the 
accumulation of a sub-G1 population of cells, indicative of induction of 
apoptosis. In addition, CYC202 caused accumulation of cells in the G2/M 
phases of the cell cycle at both concentrations investigated.In this study, 
the induction of apoptosis by CYC202 was quantified by DNA content 
analysis. Cells with a DNA content that is less than that of a cell in G1 
(termed sub-G1 peak analysis) were scored as apoptotic. In a separate 
experiment the appearance of sub-G1 peaks was confirmed to be 
representative of apoptosis by TUNEL analysis of replicate samples. 
Apoptosis was detectable at 24 h in CYC202-treated cells. 48 hour 
exposure resulted in a small further increase in the proportion of apoptotic 
cells. TUNEL analysis also demonstrated that apoptotic cells (i.e. TUNEL 
positive) were produced from each of the cell cycle compartments. This 
indicates that the previously described G2 accumulation is not a result of 
selective induction of apoptosis from the other compartments (G1 and S) 
and is likely to be caused by inhibition of one or more cell cycle 
regulators. 
 
Schutte et al. (1997) [105] studied the effect of roscovitine and its 
analogue olomoucine on cell cycle kinetics in the non-small cell lung 
cancer line MR65 and the neuroblastoma cell line CHP-212. The cells 
were pulse-labelled with bromodeoxyuridine, and were then incubated 
with roscovitine (10-40μM) or olomoucine (10-200μM). After being 
harvested at intervals the cells were subjected to irnmunocytochemical 
staining for bromodeoxyuridine and treatment with propidium iodide, 
followed by flow cytometric analysis. Dose-dependent inhibition of both 
the G1-S and G2/M-G1 phase transitions was observed, as well as slowed 
progression through S-Phase with both CDK inhibitors, although 
roscovitine was approximately 10-fold more potent than olomoucine. At 
the highest concentrations tested, both inhibitors induced a complete cell 
cycle block in both cell lines and causeddetachment of the cells from the 
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culture dish, membrane blebbing, chromatin 
aggregation/condensation/fragmentation, and the disintegration of the 
nucleus, suggesting that apoptosis had been induced. Levels of CDK1 
were reduced by treatment with the CDK inhibitors as measured by 
western blotting. 
 
Alessi et al. (1998) [106] investigated the effects of roscovitine, 
olomoucine and iso-olomoucine on the cell cycle of normal human 
fibroblasts in cell culture. Roscovitine and olomoucine (but not iso-
olomoucine) induced a dose-dependent arrest in the G1-phase, which was 
reversible upon removal of the inhibitors. Western blot and 
immunohistochemical analyses of proliferating cell nuclear antigen 
(PCNA) and Cyclins D1 and E showed that levels of these were 
unaffected by treatment with either CYC202 orolomoucine. Treatment 
with the CDK inhibitors caused a reduction in the level of hyper-
phosphorylated forms of the Rbprotein. Immunoprecipitated CDK2 from 
roscovitine or olomoucine treated cells had reduced activity compared 
with control; unlike CDK4, whose activity, when immunoprecipitated 
from treated cells, remained unchanged. Overall, the authors suggested 
that their experimental results pointed to CDK2 being the cellular target of 
the roscovitine and olomoucine. 
 
Yakisichet al. (1999) [107] have reported the effects of roscovitine on 
DNA synthesis in tissue samplestaken from eight human malignant 
gliomas. Immediately, following resection, the tissue samples were cut 
into small fragments and incubated in culture medium in the presence of 
roscovitine (1-100µM). DNA synthesis was estimated by measuring the 
incorporation of tritiatedmethyl-thymidine. Roscovitine was found to 
inhibit DNA synthesis in a dose-dependent manner, an effect which was 
evident within 30 minutes from the start of the incubation. The highest 
concentration tested (100µM) inhibited DNA synthesis in the tissue 
fragments by 71-97% (mean 89%) in comparison with the control. 
 
Iseki et al., (1997) [108] studied the ability of roscovitine and olomoucine 
(an analogue ofCYC202) to block CDK1 and CDK2 activity in the human 
gastric cancer cell line SUA, and inhibit the proliferation of this cell line 
                                                      Seliciclib - discovery and development 
 
 
 
BioDiscovery                                  27                         December  2013 | Issue 10 | 1 
 
and three other human gastric cancer cell lines (AGS, MKN45-630 and 
SNU-I) in cell culture. Both roscovitine and olomoucine blocked 
inhibition of Histone H1, a proxy for CDK1 and CDK2 activity in SIIA 
cells, induced a large increase in the proportion of cells in the G2/M and S 
phases of the cell cycle, and also inhibited the proliferation of all four 
gastric cancer cell lines tested. The same group carried out a similar study 
using four human pancreatic cancer cell lines with a variety of genetic 
alterations (BxPC3, PANC-I, Capan-2 and CAV), and showed that both 
roscovitine and olomoucine blocked CDK2 activity in all four pancreatic 
cell lines and inhibited cell proliferation [109] in a dose dependent 
manner, independent of the K-Ras, p53 or p16 status of the cell lines, and 
thus suggested that CYC202 represented potential new therapeutics for 
pancreatic cancer. 
 
Mgbonyebi et al, (1998) [110] investigated the effects of roscovitine on 
proliferation of immortal and neoplastic human breast epithelial cells in 
cell culture. The human breast epithelial cell lines studied were MCF-7 
(oestrogen receptor-positive carcinoma), MD-MB-231 (oestrogen 
receptor-negative carcinoma) and MCF-10F (immortalised oestrogen 
receptor-positive). Treatment with roscovitine (1-40μg/mL) resulted in a 
dose and time-dependent inhibition of the proliferation of all three cell 
lines, suggesting a role for CYC202 in the treatment on both ER-ve and 
ER+ve breast tumours. Further studies by the same group on the nature of 
the inhibition in the MD-MB-231 cell line revealed that treatment with 
roscovitine (10μg/mL for 24–240 hours) induced cell death and 
morphological changes, such ascell shrinkage, chromatin condensation, 
changes in actin microfilament architecture, and extensive detachment of 
cells from the cell culture substratum, consistent with the induction of 
apoptosis [111]. 
 
In addition to its cytostatic and pro-apoptotic actions,roscovitine has also 
been reported to induce cell differentiation. In a study using the human 
non-small cell lung cancer cell line NCI-H348 [112] induction of 
mucinous differentiation was observed in NCI-H348 cells treated with 
10μM roscovitine for 24 or 72 hours, as indicated by the development of 
positivity for periodic acid-schiff (PAS) staining. 
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The cellular effects of roscovitine have also been investigated in several 
non-mammalian models [99].Roscovitinehas been shown to arrest starfish 
oocytes and sea urchin embryos reversibly in late prophase, and showed in 
vitro inhibition of M-phase promoting factor activity and DNA synthesis 
in Xenopus egg extracts. The compound has also blocked progesterone-
induced maturation of Xenopus oocytes, and in vivo phosphorylation of 
the elongation factor eEF-1. 
 
Roscovitine was reported to induce apoptosis in several cell lines, 
regardless of p53 status; surprisingly, roscovitine was more effective in 
inducing apoptosis in wild type p53 cells, compared to p53 null cells. Cell 
death has been detected in all phases of the cell cycle, and different 
mechanisms may be involved, including inhibition of the cell cycle due to 
p53 activation and inhibition of CDK7/CDK9-dependent transcription 
inhibiting RNA polymerase II enzyme [113,114]. The effect of roscovitine 
on global transcription was shown to be limited, and only few proteins, 
including Mcl-1, XIAP, and survivin, were found to be reduced. Thus, cell 
death caused by roscovitine seems to be correlated rather well with 
inhibition of transcription of essential cell survival factors [115, 116]. It 
has been shown that downregulation of survivin and XIAP by roscovitine 
contributes to the activation of caspases in glioma cells. Alvi et al. [117] 
have reported that roscovitine induced apoptotic cell death in chronic 
lymphocytic leukemia B-lymphocytes at significantly higher levels, 
compared to that observed in normal blood mononuclear cells, purified B- 
or T-lymphocytes. The apoptosis process was shown to be caspase-
dependent, but p53-independent, and was accompanied by downregulation 
of Mcl-1 and XIA [118]. 
 
The antitumor effects of roscovitine are mainly based on anti-proliferative 
and pro-apoptotic mechanisms; moreover, no resistance to roscovitine 
therapy has been reported so far [119]. 
 
Interestingly, tumor cells are more dependent on short-lived survival 
factors than normal cells. Thus, downregulation of these factors by 
roscovitine treatment has higher impact on tumor cells than on normal 
cells [120]. Roscovitine showed synergistic effects in combination with 
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other chemotherapeutic agents in vitro, e.g. camptothecin in MCF-7 breast 
tumor [121], histone deacetylase (LAQ824) in HL60 and Jurkat leukemic 
cells, doxorubicin in sarcoma cell lines [122] and irinotecan in p53-
mutated colon cancer [123]. 
 
6. Anti-tumour activity of CYC202 in vivo 
 
Roscovitine has been examined in a variety of cell lines from a 
number of different tissue types for anti-tumour activity in mouse 
xenograft models. Its anti-tumour activity is best described as mild, with 
reductions in tumour cell growth observed, rather than reductions in initial 
tumour cell volume. The compound has been delivered both orally and via 
intra-peritoneal injection, and a number of doses and dosing schedules 
have been employed. McClue and co-workers used the uterine cell line 
MES-SA/Dx5 and the colon cell line LOVO, which had been most 
sensitive to CYC202 in an in vitro, 19 member cell line panel. Mice 
bearing established tumours formed from LOVO were dosed with 
100mg/kg CYC202 three times daily by intra-peritoneal injection for 5 
days, and tumour growth was followed for 32 days post initiation of 
dosing, at which point CYC202 treated animals bore tumours that were 
approximately 55% of the volume of those of the control animals [100]. In 
another study mice bearing MES-SA/Dx5 tumours were dosed with either 
200mg/kg or 500mg/kg of CYC202 by intra-peritoneal injection three 
times per day for either 10 days or 4 days, respectively. Again anti-tumour 
activity was mild with tumour growth inhibited by 35% at the 200mg/kg 
dose and by 62% at 500mg/kg [100]. 
 
Most other studies using roscovitine as a single agent have seen similar 
anti-tumour activities in xenografts using cell lines of colon, lung, brain, 
breast and nasopharangeal origin [124–128]. Interestingly, a study dosing 
mice bearing an Ewing’s Sarcoma cell line A4573 with only 50mg/kg of 
roscovitine once per day has shown the most striking single-agent anti-
tumour activity, inhibiting tumour growth by 85%, when compared to 
untreated animals [129]. Our results and data form other laboratories on 
anti-tumour activity of CYC202 in vivo are summarised in Table 3. 
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Table 3. In vivo anti-tumour activities of Roscovitine in xenografts. 
 
 
Roscovitine has also been tested for anti-tumour activity in xenograft 
models in combination with ionising radiation and other small molecule 
kinase inhibitors, with sometimes impressive results (Table 4). Most 
striking is the anti-tumour activity seen with the combination of 50mg/kg 
roscovitine dosed twice per day for 5 days by intra-peritoneal injection, 
followed by a two day break, and a further 5 days of dosing in 
combination with a dose of 6Gy ionising radiation twice in the same 
dosing period. This treatment caused a reduction in tumour growth of 
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around 95% in two Epstein-Barr Virus (EBV) positive cell lines derived 
from nasopharyngeal carcinomas [126]. Maggiorella and co-workers also 
utilised ionising radiation in combination with roscovitine, and achieved 
an 80% reduction in tumour growth, compared to untreated animals over 
the 30 days following treatment [130]. 
 
In combination with other small molecule kinase inhibitors roscovitine has 
produced tumour growth inhibitions of around 75-93%, compared to 
untreated animals. Used together with erlotinib to treat mice carrying 
H358 (non-small cell lung cancer) tumours, Fleming and co-workers 
report that, when CYC202 was dosed at 50mg/kg twice per day for 5 days 
on / 2 days off for 28 days, and erlotinib was dosed orally, daily at 
100mg/kg for all of the 28 days treatment period, tumour growth was 
reduced by 93% 7 weeks after the treatment was started. In the same study 
CYC202 alone, when dosed using the same schedule, failed to 
significantly inhibit tumour growth, and erlotinib inhibited only to 56% of 
untreated control, indicating some synergistic activity between the 
molecular targets of CYC202 and erlotinib. 
 
Roscovitine has also been used successfully in combination with the small 
molecule PI3-Kinase inhibitor PIK-90 to inhibit growth of GBM43, 
glioma derived tumours, in immunodeficient mice. Dosedby intra-
peritoneal injection at 50mg/kg, four times daily for 12 days together with 
PIK-90 four times per day at 40mg/kg, tumour volume was about 25% of 
that in untreated animals. Roscovitine when used as a single agent, 
inhibited growth by about 40% in the same model. 
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7. Pharmacokinetics and pharmacodynamics of 
roscovitine 
 
7.1. Pharmacokinetics and metabolism of roscovitine 
The pharmacokinetics of roscovitine was studied in mice, rats and humans. 
Vita et al. [131] described roscovitine PK in rat as a two-compartment open 
model with a short elimination half-life of <30 min (Table 5). 
 
Table 5. Pharmacokinetics of roscovitine in rats following i.v. administration 
at a dose of 25 mg/kg. 
AUC: Area Under the Curve; T½-α: the distribution half-life;  
T½/ T½-β: the terminal elimination half-life; CL: Clearance; Vd: Distribution 
Volume  
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The distribution of roscovitine was highest in the lungs, followed by liver, 
fat, and kidney, while exposure to roscovitine in the brain was 30% of that 
observed in plasma (Figure 6). 
 
 
 
Figure 6. Organ exposure to roscovitine () and it major metabolite () in 
rats after bolus administration of 25 mg/kg body weight expressed as AUC ± 
SD. 
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Three major metabolites were detected in plasma (Figure 7). 
 
 
Figure 7. Roscovitine metabolites detected in rat plasma. 
 
The first metabolite is the major metabolite. It is a carboxylated form of 
roscovitine, while the second metabolite is the glucuronide form of 
metabolite one. No metabolites were detected in the brain (Figure 8) [131, 
132]. High protein binding of roscovitine (92% to 96%) was shown in 
human and mouse plasma [124, 133]. 
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Figure 8. The distribution of roscovitine and it’s major metabolite in 
different organs of the rat after the administration of a single dose of 25 
mg/kg. 
Pharmacokinetics of roscovitine was investigated in BALB/c and Tg26 
mice. These studies showed rapid and biphasic clearance of roscovitine 
from plasma following i.v., i.p. or oral administration [124, 134, 135]. 
Roscovitine had rapid tissue distribution and rapid elimination with a half-
life of 1.19hr. Plasma concentrations above 15μM (the average IC50values 
obtained with various tumor cell lines) were observed for 4, 12, and 24hr 
following oral administration of 50, 500, and 2000mg/kg, respectively 
[124]. 
 
The pharmacokinetics of roscovitine in humans were reported in two phase-
I trials. Roscovitine was administered orally as a single dose (50 to 800mg) 
to healthy volunteers and the concentrations of roscovitine and its 
carboxylated metabolite were followed in plasma and urine. Roscovitine 
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was found to undergo slow absorption from the gastrointestinal tract (GIT); 
however, the bioavailability of the drug was not affected by food intake. 
Roscovitine was found to have rapid metabolism and non-saturated high 
protein binding [136]. 
 
Twenty-one patients with a median age of 62 years (range: 39–73 years) 
were treated with roscovitine in doses of 100, 200 and 800mg twice daily 
for 7 days. The elimination half-life was found to be dose dependent and 
ranged between 2–5hr. Neither objective tumor responses nor inhibitions of 
retinoblastoma protein phosphorylation (PD endpoint) in mononuclear cells 
in peripheral blood were observed[137]. 
 
In vitro and in vivo metabolism of roscovitine was reported recently[131, 
135, 138, 139]. Several metabolites were identified, including the 
carboxylate metabolite (oxidation of the alcohol group at C2 of the purine 
ring)[131]. Cytochrome P450, mainly CYP3A4 and CYP2B6 enzymes, has 
been shown to metabolize roscovitine. Roscovitine was found to undergo 
phase II metabolism through conjugation with glucoronic acid by the phase 
II UGT1A3, 1A9 and 2B7. Moreover, roscovitine was able to inhibit its 
own metabolism in vitro through inhibition of CYP3A4 with an IC50 of 
3.2µM. Thus, possible drug-drug interactions should be considered in the 
clinic[139]. 
 
7.2. Chronopharmacology of roscovitine 
Treatment effect of roscovitine in non-nude BDF1 male mice bearing 
Glasgow osteosarcoma xenografts was investigated in relation to biological 
circadian rhythm. Roscovitine was administered orally (300 mg/kg ×1 
daily) for 5 days at Zeitgeber time 3 (ZT3, 3 hours after light onset), or 
ZT11, or ZT19. Roscovitine reduced tumor growth by 35% when 
administered during the active time of the mice (ZT19), and 55% when 
administered during their rest span (ZT3 or ZT11) [140]. 
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7.3. Pharmacokinetics and pharmacodynamics of 
roscovitine in mouse bone marrow  
Myelosuppression is the dose-limiting factor for the majority of 
conventional chemotherapeutic anticancer agents and one of the most 
frequent complications. Chemotherapy may induce partial or complete 
myeloablation of the bone marrow, which in general is dose dependent. 
Studies on hematotoxicity in vitro and in animal models help to predict 
possible side effects before the start of clinical trials.  
 
In a recent study, we investigated the myelosuppressive potential of 
roscovitine on bone marrow cells in vitro and in vivo in Balb/c mice. Bone 
marrow was incubated in vitro with roscovitine at concentrations of 25–
250µM for 4hr and viability was studied using resazurin assay. Bone 
marrow cell viability was decreased in a concentration-dependent manner. 
At a concentration of 250µM, cell viability was significantly (p=0.015) 
reduced to 70%, compared to control mice, while significant effect was 
observed at lower concentrations. These results were in agreement with the 
findings that roscovitine induced apoptosis of mature neutrophils [141], 
eosinophils [142]. and proliferating T-cells [143] in a concentration and 
exposure-time dependent manner. 
 
The myelosuppressive effect of roscovitine on hematopoietic progenitors 
was studied using clonogenic assay[144]. Bone marrow cells were 
incubated with roscovitine (25–100µM) for different time intervals up to 
24hr. After washing, the capacity of hematopoietic progenitors to form 
colony-forming unit granulocyte/macrophage (CFU-GM), burst-forming 
unit erythroid (BFU-E), and colony-forming unit 
granulocyte/erythrocyte/macrophage/megakaryocyte (CFU-GEMM) 
colonies was studied using semisolid media. The clonogenic capacity of the 
bone marrow decreased in a dose- and time-dependent manner. BFU-E 
colonies were more sensitive compared to CFU-GM. BFU-E were 
completely blocked after 12 and 24hr incubation with both 50 and 100µM 
of roscovitine. Since the decrease in colony formation in controls after 12 
and 24hr most probably is due to lack of growth factors in the suspension 
media, bone marrow cells were exposed to roscovitine (1–100µM) in 
semisolid MethoCult media containing growth factors. Suppression of 
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colony formation in a concentration- and cell type-dependent manner was 
observed. CFU-GEMM were most sensitive and were completely blocked 
at 25µM concentration, followed by BFU-E which were also significantly 
inhibited at 25µM, while CFU-GM were least sensitive and were inhibited 
at 100µM only. 
 
We further studied the myelosuppressive effect of roscovitine in vivo in 
female Balb/c mice. Mice were treated with roscovitine, and bone marrow 
cells were cultured in the MethoCult media and assessed for clonogenic 
growth. After the administration of a single dose of roscovitine up to 
250mg/kg, no myelosuppressive effect was detected. However, the 
administration of roscovitine at 175mg/kg twice daily for 4 days resulted in 
only transient inhibition of the BFU-E colonies, which was observed one 
day after the last dose of roscovitine. Colony formation capacity of bone 
marrow was recovered 5 days after the last dose of roscovitine (Figure 9). 
 
The lack of activity of roscovitine on hematopoietic progenitors in vivo was 
not expected, since an inhibitory effect in vitro was observed, along with the 
reported activity on different xenografts in vivo[100,124, 129,140]. 
Therefore, we decided to study the distribution and PK of roscovitine in 
Balb/c mice. Roscovitine was administered as a single i.p. injection in a 
dose of 50 mg/kg. As presented in Table 5, roscovitine had a short half-life 
(less than 1hr), and only a small fraction of roscovitine (about 1.5%) 
reached the bone marrow compared to plasma. Thus, low distribution of 
roscovitine to bone marrow may explain the low hematotoxicity in vivo. 
This study is an excellent example illustrating the importance of PK/PD and 
biodistribution investigations in preclinical studies. This may also show 
that, despite the good cytotoxic effect of roscovitine in leukemic cell lines in 
vitro, its therapeutic potential in hematological malignancies may be rather 
limited. 
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Figure 9. Effect of roscovitine on hematopoietic progenitors in vivo. Mice 
were treated with roscovitine (350 mg/kg/day) for 4 days divided into two 
daily doses. Mice treated with DMSO and untreated animals served as 
controls. Bone marrow was examined 1 and 5 days after the last dose of 
roscovitine. CFU-GM, BFU-E and CFU-GEMM were counted on day 12. 
Each group consisted of five mice, and the control group of eight mice. 
Results are expressed as mean ± SD. 
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7.4. Age-dependent kinetics and pharmacodynamics of 
roscovitine in rat brain 
In the field of pediatric medicine, especially when the drug has a narrow 
therapeutic window, age-dependent pharmacokinetics becomes an 
important issue. Unfortunately, scaling down the PK data from adults to 
pediatrics has proved not to be predictive enough for many drugs. [145] 
Roscovitine was reported to inhibit different solid and hematological tumor 
cell lines, including ALL[146], which is frequent in children and is 
correlated with a high CNS relapse rate [147]. 
 
A recent study reported the effects of age on the pharmacokinetics of 
roscovitine and investigated the effect of roscovitine on two neuronal 
targets, CDK5 and Erk1/2, in different regions of the brain [148]. Fourteen-
day-old pups and adult Sprague-Dawley rats were treated with a single i.p. 
injection of roscovitine at a dose of 25mg/kg. Plasma and brain were 
sampled at different time points. The pharmacokinetic parameters of 
roscovitine in plasma and in different brain regions in pups and adult rats 
are given in Table 6. The pharmacokinetics of roscovitine was fitted to a 2-
compartment open model, with distribution half-lives of 0.6hr in pups and 
0.06hr in adult rats. The elimination half-life (7hr) observed in plasma and 
brain of the rat pups was significantly longer compared to that observed in 
plasma and brain in adult rats (30 and 20 min, respectively).  
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Table 6. Pharmacokinetics of roscovitine in rat plasma and brain parts after 
single i.p. administration (25mg/kg). Abbreviations: AUC, area under the 
concentration-time curve; Tα, absorption half-life; Tβ, elimination half-life; Cmax, 
maximum reached concentration; Vss, volume of distribution at steady state; CL, 
clearance. 
 
PK 
parameters Plasma 
Frontal 
Cortex Hippocampus Cerebellum 
 AUC 
(h.μg/ml) 
3.01 ± 
0.21 0.71 ± 0.14  0.58 ± 0.03  0.62 ± 0.06 
Tα (h)  
0.081 ± 
0.05  0.045 ± 0.02  0.062 ± 0.012  
0.062 ± 
0.018  
Tβ (h) 
0.54 ± 
0.26 
0.35 ± 0.13 0.36 ± 0.15 0.42 ± 0.18 
Cmax 
(μg/ml) 
17.71 ± 
4.42 4.47 ± 0.70 4.64 ± 0.81  3.81 ± 1.22  
Vss(ml)  650 ± 223  1095 ± 167  2056 ± 219  1909 ± 484  
CL (ml/h)  1637 ± 
118  
7262 ± 1612  8737 ± 452  8139 ± 727  
 
The exposure to roscovitine expressed as AUC was 22-fold higher in pup 
plasma and 100-fold higher in pup brain tissue, compared to that seen in 
adult rats (Figure 10). However, no significant difference was observed 
between roscovitine AUC in plasma and AUCs in different brain regions in 
pups. On the contrary, in adult rats the AUC of roscovitine in the brain was 
about 25% of that found in plasma (Table 6). The maximum observed 
concentration (cmax) was significantly (p<0.05) higher (>22µg/g) in pup 
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brain tissue, compared to that found in plasma. However, 4-fold higher cmax 
was found in plasma, compared to that observed in the brain (17.7µg/ml and 
about 4µg/g, respectively) of adult rats. The high concentrations of 
roscovitine found in pup brain tissue indicate that roscovitine passes freely 
through the blood brain barrier (BBB). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.Concentration versus time curves of roscovitine after fitting to a 
two-compartment open model in the plasma (to the left) and different brain 
regions (to the right) in 14-day-old rat pups and adult rats following single 
i.p. administration of 25 mg/kg. The solid and dashed lines represent the 
theoretical model.   
 
This difference in roscovitine kinetics might be due to the immaturity of the 
CYP450 enzymes responsible for roscovitine metabolism [149] or to the 
immaturity of the BBB. Roscovitine is metabolized mainly by the CYP3A4 
and CYP2B6 enzymes in human [139]. Several CYP450 enzymes are not 
fully matured in rats at two weeks of age [150]. A similar situation was also 
reported in humans; CYP3A4, for example, only approaches full maturity 
after the first year of life [151, 152]. 
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Most chemotherapeutic agents do not cross the blood brain barrier (BBB) 
and do not reach the CNS in high enough concentrations to eliminate tumor 
cells despite high systemic exposure. Roscovitine was highly presented in 
the brain of rat pups, and the exposure was observed in all studied regions 
(e.g. hippocampus, cerebral cortex and cerebellum). The brain exposure to 
roscovitine was 100% of that found in plasma, which can be compared to 
about 25% of that found in the brain of adult rats. The high distribution to 
the brain could be explained by an age-dependent variation in the maturity 
and function of the BBB. Butt et al. have reported that the BBB of the rat 
reaches full maturity 3–4 weeks after birth. [153] Roscovitine metabolites 
were not found in the brains of adult or young rats, probably due to their 
hydrophilic character. 
 
Roscovitine concentrations in plasma and brain of rat pups were higher than 
the IC50(10–15µM) reported for cancer cell lines for more than 8 hours. 
However, this level of exposure was achieved only for short time (<30 
minutes) in plasma and brain of adult rats. These results may be utilized in 
the treatment of pediatric brain tumors. 
 
Roscovitine has been reported to be a potent inhibitor of CDK5 that has an 
important function in the developing brain, such as neuronal migration [11]. 
Moreover, the negative feedback regulation of mitogen activated protein 
kinases (MAPK) signaling by CDK5 was suggested to be essential for 
neuronal survival [154]. 
 
The unexpected high concentrations of roscovitine in the brain of rat pups 
led us to assess the expression of p35 as an indicator of CDK5 activity. It is 
well known that the inhibition of p35 phosphorylation by CDK5 stabilizes it 
and delays its proteasomal degradation [155, 156]. We found that 
roscovitine induces a transient and significant accumulation of p35 protein 
in all brain regions in rat pups, which indicates inhibition of the CDK5 
enzyme. Furthermore, increase in p35 was found in the frontal cortex about 
1–2hr post-administration (140% in controls; Figure 7;p <0.05), in the 
hippocampus and in the cerebellum at 2hr post-administration (150% and 
200%, respectively; Figure 11). The levels of p35 reached the normal level 
at 6–15hr post-administration. Surprisingly, no change in p35 levels was 
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observed in the brain of adult rats, which is most probably due to the low 
concentration and the short elimination half-life. 
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Figure 11.Effect of roscovitine on Cdk5-p35 in different brain parts of 14-
day-old rat pups after single i.p. injection of 25 mg/kg. Pups were sacrificed 
at different time points after injection, and their brains were dissected, 
homogenized, and immunoblotted for active Cdk5-p35. The figure shows 
densitometric analysis of the Western blotting bands for p35 in the frontal 
cortex, hippocampus and cerebellum until 48 hr after single i.p. injection of 
roscovitine. Data are presented as mean± SD of values expressed as 
percentage of control animals (*, p < 0.05 for analysis of p35 data; ANOVA 
followed by Fisher’s PLSD post-hoc test). 
 
 
CDK5 was found to inhibit Erk1/2 phosphorylation by a MEK1 and 
RasGRF2 mediated mechanism. Moreover, it was reported that the 
inhibition of CDK5 by roscovitine increased the levels of phosphorylated 
Erk1/2 (active form) in neuronal cells in vitro[154, 157]. Soon after the 
administration of roscovitine, the accumulation of p35 protein was 
accompanied by increased levels of the phosphorylated (activated) form of  
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Erk1/2. A transient activation of Erk1/2 was observed at 1 and 2hr after 
administration in the frontal cortex and hippocampus (Figure 8). In the 
cerebellum, a significant increase of pErk1/2 levels at 2hr was followed by 
a significant decrease at 6hr after roscovitine administration (Figure 12). 
The levels of pErk1/2 returned to normal levels in all brain regions at later 
time points (Figure 12). 
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Figure 12. Effect of roscovitine on pErk in brain regions of 14-day-old rat 
pups after single i.p. injection of 25 mg/kg. Pups were sacrificed at different 
time points post injection. Their brains were dissected, homogenized, and 
immunoblotted for active phosphorylated Erk1/2. Control animals were 
injected with vehicle. The figure shows densitometric analysis of the 
Western blotting bands for pErk1/2 in the frontal cortex, hippocampus and 
cerebellum until 48 hr after single i.p. injection of roscovitine. Data are 
presented as mean± SD of values expressed as percentage of control animals 
(*, p < 0.05 is the significant level for analysis of pErk data; ANOVA 
followed by Fisher’s PLSD post-hoc test). 
These results show that roscovitine levels in the brain of rat pups were 
sufficient to inhibit CDK5, resulting in increased phosphorylation of 
Erk1/2. 
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7.5. Summary and future outlook 
Cyclin-dependent kinases (CDKs) are essential kinases and play a key role 
in cell cycle progression and RNA transcription. The deregulation of CDKs 
has been described in several diseases, including cancer. The cyclin 
dependent kinase inhibitors (CDKIs) are synthetic small heterocyclic 
compounds that compete with ATP and inhibit the phosphorylation of the 
target substrates. Based on this knowledge, exposure of tumor cells to 
CDKIs will result in both cell cycle arrest and apoptosis. 
 
2,6,9-trisubstituted purines are among the first described CDK inhibitors 
[158]. The (R)-stereoisomer of roscovitine is a member of this family that 
recently reached phase-II clinical trials for nasopharyngeal cancers and non-
small cell lung cancer (NSCLC), as well as phase-I trials for 
glomerulonephritis. Several preclinical studies about the role of roscovitine 
in the treatment of neurodegenerative disorders, e.g. Alzheimer’s disease, 
viral infections, protozoal infections, and inflammatory diseases, are 
ongoing. The poor pharmacokinetic profile (rapid metabolism and short 
elimination half-life in rodents and man) and the insufficient exposure to the 
drug in cancer patients may explain the modest success in clinical 
trials[124, 131, 135-137]. Several attempts to overcome pharmacokinetic 
barriers that limit the clinical use of roscovitine are ongoing. At the same 
time, second-generation analogues of roscovitine have been designed and 
are under development. Studies on the pan-CDK inhibitor, flavopiridol, 
confirmed the importance of optimizing the dosing schedule according to 
the PK/PD relationship. By changing the dosing schedule from 72hr 
infusion to 30 minutes i.v. bolus followed by 4-hr-infusion a significant 
difference in the clinical outcome and final response of refractory CLL 
patients was achieved[159]. 
 
The absence of myelosuppression, reported in preclinical and clinical 
studies of roscovitine [134, 137], is clinically beneficial. However, low 
hematotoxicity of roscovitine might in reality reflect poor distribution of 
roscovitine to the bone marrow. The hematopoietic progenitors were 
inhibited by roscovitine in vitro within the same exposure range as the 
tumor cells, when comparing the inhibitory AUC reported for tumor cell 
lines [100,124] with the inhibitory AUC of the hematopoietic progenitors 
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found in our study. The hematotoxicity of roscovitine may become more 
evident under the following conditions: 
1. Changes of the administration form to increase the 
half-life of the drug may result in changes in biodistribution and 
higher exposure to roscovitine, and thus change its toxicity profile. 
2. Radiation therapy increases the permeability of the 
blood-bone marrow barrier [160]. A combination of roscovitine with 
radiotherapy may increase the myelotoxicity of roscovitine. 
3. Higher bone marrow exposure to roscovitine and thus 
a higher toxicity risk may occur in pediatric patients due to age-
dependent pharmacokinetics [151]. 
 
Age-dependent pharmacokinetics is not a unique factor for roscovitine. 
Age-dependent pharmacokinetics has been reported for several drugs, 
including cisplatin, busulfan, thioguanine, etoposide, lamivudine, and 
mycophenolate mofetil [161-166]. Our studies showed that roscovitine 
elimination half-life was 14-fold higher in young rats compared to adults. 
Moreover, the exposure to roscovitine was 22-fold and 100-fold higher in 
plasma and brain, respectively. Age-dependent pharmacokinetics is an 
important issue in toxic drugs and drugs with a narrow therapeutic window, 
such as anticancer drugs. In these drugs, underdosing may lead to relapse, 
while overdosing can cause severe side effects. 
 
8. Clinical results from investigation of Seliciclib in 
clinical trials 
 
To date, CYC202 has been evaluated in several phase I and II studies 
sponsored by Cyclacel Pharmaceuticals Inc. as Seliciclib, and has shown 
signs of anti-cancer activity in approximately 240 out of 450 patients. 
 
In a phase I trial Seliciclib was used to treat 21 pre-treated patients with 
refractory solid tumours. Dosing was started at 100mg twice per day for 7 
days in a 3 week cycle and dose was escalated 100% after at least 3 
patients had been treated at a given dose. Dose-limiting toxicities were 
seen with the 800mg dose schedule and included fatigue, rash, 
hyponatraemia, and hypokalaemia, with other reactions seen, including 
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increased creatinine, vomiting, and indications of abnormal liver function. 
Pharmacokinetic analyses showed that Seliciclib reached a maximum 
plasma concentration between 1 and 4 hours post dosing and that 
elimination half-life was between 2 and 5 hours. Stable disease was 
observed in 8 patients, including an ovarian cancer patient who was stable 
over 18 weeks of treatment. No tumour responses were observed [137]. 
 
In another phase I trial dosing Seliciclib orally as a single agent, 56 
patients were dosed while examining 3 different dosing schedules. 
Schedule A dosed Seliciclib twice per day for 5 days every 3 weeks, 
schedule B dosed twice-daily for 10 days followed by a 2 week break, and 
schedule C dosed twice-daily for 3 days every 2 weeks. Dosing was 
initiated at 100mg Seliciclib twice per day with dose incremented up to 
1600mg Seliciclib twice per day in schedule A, and 1800mg twice per day 
inschedule C. Schedule B was discontinued, due to the appearance of 
toxicities at lower doses than the alternative schedules. Pharmacokinetic 
analysis of plasma samples showed that exposure to Seliciclib was dose-
dependent. The dose-limiting toxicities experienced by patients were 
hypokalaemia, asthaenia, nausea, and vomiting, with other reactions seen, 
including increases in serum creatinine and indications of liver toxicity. A 
single patient with a hepatocellular carcinoma had a partial response and 
other patients had periods of stable disease. The recommended dose for 
subsequent studies was concluded to be 1250mg twice per day for 5 days 
in a 21 day cycle, or 1600mg of Seliciclib twice per day for 3 days in a 14 
day cycle [167]. 
 
CYC202 has also been tested in a phase I trial in combination with the 
current first line treatment for NSCLC Gemcitabine 1000mg/m2+ 
Cisplatin 75mg/m2. A total of 27 patients were enrolled and were dosed in 
a 21 day cycle with current first line NSCLC therapy (Gemcitabine 
1000mg/m2i.v. (days 5 and 12) and Cisplatin 75mg/m2 i.v. (day 5) plus 
oral twice per day CYC202 at either 400mg, 800mg or 1200mg (days 1–4, 
8–11, 15–18, respectively). No dose limiting toxicities (DLT) were seen at 
the lowest dose of CYC202 from 2 patients enrolled, 3 DLTs were seen in 
the 800mg CYC202 cohort from 19 patients dosed, and 3 DLTs were seen 
in the 1200mg CYC202 cohort from 6 patients dosed. The toxicities 
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observed were: elevated GGT, nausea, vomiting, hypokalaemia. 
Haematological toxicity was low. The maximum tolerated dose (MTD) 
was determined as 800mg CYC202 in combination with Gemcitabine 
(1000mg/m2) and Cisplatin (75mg/m2) within the dose schedule described 
above [168]. 
 
Interim results are available from an initial tolerability section of a phase I 
clinical trial in which 23 patients with nasopharyngeal cancer and other 
solid tumours were dosed orally with CYC202. Patients were divided into 
2 groups, one was dosed with twice-daily 400mg of CYC202 for 4 days 
per week for 2 weeks and the other group was dosed with 800mg of 
CYC202 for 4 days per week for 2 weeks. 10 patients with NPC were 
enrolled in this section of the trial and 7 had stable disease while on trial. 
Thirteen patients with other advanced solid tumours were enrolled in the 
tolerability and 4 of these patients had stable disease while on trial. Seven 
patients had progressive disease and 5 patients could not be evaluated. 
Dose-limiting toxicities (grade 3 increase in ALT or AST (n=3) and 
treatment delay of >2 weeks due to grade 1 creatinine (n=1)) were 
observed in 4 patients, and so both dosing regimes were considered as 
tolerable and could be advanced to a randomised phase of the trial, 
uniquely with NPC patients [169]. 
 
In another trial in nasopharyngeal cancer patients with locally advanced 
disease 20 patients were treated twice-daily with either 800mg or 400mg 
of CYC202 on days 1 to 3 and 8 to 12. Three patients were treated at the 
800mg twice-daily schedule and 2 of these had dose limiting toxicities 
(grade 3 liver toxicity and grade 2 vomiting), none of the 13 patients 
dosed at 400mg twice-daily showed any significant signs of toxicity. 
Tumour biopsies were taken at day 1 (just prior to dosing) and on day 13 
(after dosing had ceased). Fifty percent of the 14 evaluable patients 
showed signs of a reduction in tumour volume and were associated with 
increases in levels of apoptosis, necrosis, and reductions in plasma EBV 
DNA levels following dosing [170]. It was promising that this short 
treatment with CYC202 had such apparently positive outcome at the lower 
dosing schedule and no limiting toxicities. 
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Seliciclib was tested in a randomised phase II clinical trial in which 187 
Non-Small Cell Lung Cancer (NSCLC) patients, with at least two prior 
treatments, were dosed with 1200mg of the drug twice per day for 3 days 
in a 2 week cycle. Although there was no statistically significant 
difference in the primary endpoint of progression free survival relative to 
placebo, patients treated with Seliciclib had a longer median survival (388 
days compared to 218 days) and the study showed that Seliciclib was safe 
at the dose level and regime used in the study (Cyclacel website – 
www.cyclacel.com). 
 
Phase I clinical trial with dose expansion to determine the maximum 
tolerated dose of liposomal Doxorubicin in combination with Seliciclib for 
the treatment of patients with metastatic triple negative breast cancer was 
initiated in 2011 (Cyclacel website – www.cyclacel.com). 
 
Seliciclib has been entered into novel clinical trials in combination with 
other drugs. Phase 1 escalation trial started in 2013 of a nucleoside 
analogue Sapacitabine (CYC682), and Seliciclib, as an orally-
administered sequential treatment regimen in patients with advanced solid 
tumours (Cyclacel website – www.cyclacel.com). 
 
Investigators at Vall d’Hebron University Hospital and Cyclacel 
collaborated to study the combination of Seliciclib and the Epidermal 
Growth Factor Receptor (EGFR) inhibitor Erlotininb (Tarceva®) in 
patients with advanced solid tumours. The study aimed to identify the 
recommended dose of Seliciclib and Erlotinib, and investigated the 
pharmacokinetics of the combination and some potential 
pharmacodynamic markers (Cyclacel website – www.cyclacel.com). 
 
In addition to cancer, Seliciclib has been evaluated in clinical trials for 
other disorders. In 2013 scientists at the University of Newcastle, together 
with colleagues at the University of Birmingham and Glasgow, initiated a 
clinical trial aiming to investigate the utility of Seliciclib in the treatment 
of patients with rheumatoid arthritis, who have not responded to current 
conventional treatments. 
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9. Potential therapeutic applications of Roscovitine 
 
Polcystic Kidney Disease 
Polycystic kidney disease (PKD) is one of the most common life-
threatening genetic diseases, affecting some 12.5 million people across the 
globe. The condition is normally inherited in a dominant Mendelian 
manner, but can also be passed on recessively, and causes the formation of 
multiple, fluid-filled cysts in the kidneys, causing massive enlargement 
and leading to a reduction kidney function. Three genes have been linked 
to the condition all of which manifest similar phenotypes. Polycycstic 
Kidney Disease 1 (PKD1) is the most common genetic mutation and 
accounts for about 85% of dominantly inherited cases. It is located on 
chromosome 16 and encodes polycystin-1 (PC-1), a 4303 amino acid 
transmembrane glycoprotein involved in Wnt and GPCR-coupled 
signalling and in mediating calcium channel activity [171–174). The 
protein has been found localised to the desmosome and to focal adhesion 
complexes suggesting a role in the maintenance of cell-cell adhesion. 
Indeed in PKD cells PC-1 together with other normal desmosomal 
proteins are absent from intercellular junctions, remaining in the 
cytoplasm, despite unchanged levels of expression, thus suggesting that 
expression of normal PC-1 is required for correct assembly of 
desmosomal junctions [175]. There is also evidence that the expression of 
mutated PC-1 leads to a disruption in the polarity of renal epithelial cells 
[176] causing mislocalisation of ion channels and growth factor’s 
receptors that in turn can reverse fluid flow and drive cellular proliferation 
in the kidney [177]. 
                                                                                                                  
This increased renal cell proliferation has been targeted using roscovitine, 
an approach that has met with some success. Mouse models of both 
indolent (jck) and aggressive(cpk) forms of the disease show inhibition of 
disease progress and improvements of renal function when the mice are 
treated with roscovitine [178]. In a 2006 study Bukanov and co-workers 
showed that renal cells from roscovitine treated mice suffering with 
indolent PKD showed decreased phosphorylation of Rb and Cyclin D 
levels consistent with a block at the G1/S phase of the cell cycle. 
Interestingly these effects did not require daily roscovitine dosing and the 
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benefits persisted long after dosing of the mice had been stopped. This 
short term dosing would be a highly beneficial in the treatment of  such a 
chronic condition. 
 
Glomerulornephritis 
Roscovitine has also been tested in a number of animal models of the 
kidney disease glomerulonephritis. Pippin and co-workers showed that the 
CDK inhibitor caused a reduction in mesangial cell proliferation and 
improved renal function in rats with experimental 
mesangialglomerulonephritis (Thy1 model) [179]. Podocytes or visceral 
epithelial cells are cells in the Bowman’s capsule of the kidney and loss of 
these cells is a contributing factor in glomerulosclerosis in the kidney and 
subsequent proteinuria. Rats with passive Heymann nephritis, a model 
system for membranous glomerulonephritis, showed no signs of podocyte 
damage when treated with CYC202 (R-roscovitine) for 4 weeks, 
supporting the idea that this compound could provide a safe therapeutic 
approach in renal diseases characterized by podocyte injury [180]. 
Recently in a study in Wistar rats CYC202 was dosed orally to examine its 
effect on both established glomerulonephritis and its ability to prevent 
glomerulonephritis. The compound was shown to be effective at both 
prevention of crescentic glomerulonephritis and treatment of the pre-
existing condition. The number of glomerular macrophages was reduced, 
as was a range of other disease markers, adding further weight to the 
argument that roscovitine may provide an effective therapeutic option for 
patients with, or at risk of developing, glomerulonephritis [181]. 
 
Systemic lupus erythrematosus (SLE or Lupus) is an autoimmune disease 
that can affect many parts of the body. It is characterised by the activation 
and proliferation of autoreactive T and B cells and the production of 
autoantibodies targeting endogenous antigens or nuclear antigens. This 
results in inflammation and tissue damage, and, in addition, antibody-
immune complexes can precipitate and invoke a further immune response 
[182]. These immune complexes can also be retained in the kidney, where 
they can lead to complement activation and recruitment of T cells and 
macrophages. Cytokines secreted by these recruited cells can drive 
cellular proliferation in the kidney and exacerbate any renal disease [183, 
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184]. CYC202 has been tested in the NZBxNZW model of autoimmune 
lupus nephritis [185, 186] and, when dosed early, disease progression 
successfully delayed the appearance of proteinuria and slowed the decline 
in renal function. Importantly CYC202 treatment prolonged the survival 
of the treated mice compared to untreated control animals [187]. 
 
Anti Virals 
Viruses, such as papilloma- or adeno-virus that can replicate only in 
dividing cells, have a requirement for cellular CDK activity to drive the 
cell into and through the phase of the cell cycle in which they are 
replication competent. Viruses, such as HIV and HSV, which can replicate 
in non-dividing cells, have a less obvious requirement for CDK activity, 
although some studies have revealed that, at least in vitro, replication of 
many of these viruses can be inhibited by small molecule inhibitors of the 
CDKs, such as roscovitine. 
 
Human Cytomegalovirus (HCMV) is a double stranded DNA virus 
member of the β-Herpes family of viruses. Exposure rates across the 
general population are high but infection in healthy individuals rarely has 
any serious effects, however, immune-compromised individuals can 
develop retinitis, pneumonitis or gastroenteritis, increasing morbidity and 
mortality. These complications are more commonly seen in HIV infected 
patients [188] and in the newborn, where HCMV is a relatively common 
congenital infection and treatment options are limited [189]. Efficient 
HCMV replication requires CDKs 1,2,7and 9 [190–193]. Infection 
induces a cell cycle arrest in a G1-like state with high levels of Cyclin E 
and CyclinE-associated kinase that supports productive viral replication 
[194]. HCMV infection acts to create a cellular milieu favourable to viral 
transcription, protein modification and viral-genome replication that is 
disrupted by the inhibition of CDKs by small molecule ATP antagonists, 
such as roscovitine [195, 196]. Treatment of HCMV infected cells with 
roscovitine has been shown to reduce viral DNA synthesis, production of 
viral late proteins and ultimately the production of infectious viral 
particles. CDKs have been shown to phosphorylate and modulate the 
localisation and activity of the key viral multifunctional regulator protein 
pUL69 [197] causing its co-localistion with CDK9 and Cyclin T1 in 
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intranuclear speckles. This observation, when taken together with the 
demonstration that CDK9/Cyclin T1 phosphorylates pUL69 in vitro, raises 
the possibility that CDK activity is important in regulating pUL69 
function and that small molecule inhibitors of CDKs have a future as 
HCMV therapeutics. 
 
HIV-1 gene expression is controlled by the viral Tat transactivator as well 
as host cell transcription factors (reviewed in 198–200). Tat promotes 
efficient transcriptional elongation from the HIV-LTR, increasing the 
proportion of full length transcripts transcribed [201, 202]. Tat binds to a 
bulge in the stem-loop of the transactivation response element (TAR) at 
the 5’ end of the viral transcript [203–206]. A number of host cell proteins 
interact with TAR and/or Tat to promote full transactivational activity, 
among them a protein kinase, originally designated as Tat-associated 
kinase (TAK) which phosphorylates the c-terminal domain of RNA Pol II 
[207]. It has been shown that the heptapeptide repeats of the C-terminal 
domain (CTD) of RNA Pol II are phosphorylated on Ser-2, Ser-5 and Ser-
7 during transcription and that CDK7 is responsible for the 
phosphorylation of Ser-7 [208–211]. TAK has been identified as 
CDK9/Cyclin T1 and shown to interact with the TAR loop structure [212–
214]. Ser-5 of the RNA Pol IICTD in the pre-initiation complex may be 
phosphorylated by TFIIH-associated CDK7 when induced by Tat causing 
its dissociation and allowing CDK9 autophosphorylation and efficient 
binding of CDK9/Cyclin T1 to the TAR stemloop [215–218]. In addition 
cells latently infected with HIV-1 have been shown to have increased 
CDK2/Cyclin E kinase activity due to loss of the CDKI – p21/waf1 [219]. 
These observations clearly pointed to the fact that inhibitors of CDKs 2,7 
and 9 could be of potential benefit in inhibiting HIV infection. 
Roscovitine, which exhibits CDK inhibitory activity against CDKs 2,5,7 
and 9, has been tested in vitro for its ability to inhibit HIV replication. The 
compound reduced viral titre and induced apoptosis in T-cells, monocytes 
and PBMCs, and was active against wildtype and drug resistant strains of 
the virus. Interestingly it was noted that anti-HIV activity was independent 
of the phase of the cell cycle [220]. It seems that a number of CDKs are 
involved in the efficient replication of HIV-1 and that inhibition of these 
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kinases has the real potential to significantly reduce viral load and offer 
complementary strategies inthe treatment of HIV infections. 
Herpes viruses are one of the groups of viruses that carry genes for 
protein kinases in their genome [221]. However, many viral functions rely 
on and are regulated by host cell proteins; and so inhibitors of these host 
cell functions may inhibit viral replication. Rosovitine has been shown to 
inhibit viral transcription leading to a reduction in the number of viral 
transcripts [222, 223]. CDK8 has been reported as inhibiting HSV-1 
transcription by phosphorylating the CDT of RNA Pol II prior to it being 
recruited to viral promoter sequences and by phosphorylating promoter-
bound transcription factors [224, 225]. In contrast the inhibitory effects of 
CDK8, both CDK7 and CDK9 have been shown to enhance viral 
transcription and processivity by phosphorylating sites in the CTD of 
RNA Pol II [226–231]. CDK1 and CDK2 are also capable of 
phosphorylating the CTD of RNA Pol II so have potential roles in 
transcriptional control [232–235]. Roscovitine may also inhibit viral 
transcription via its effects on chromatin structure [236]. 
 
Inflammation 
Roscovitine has been tested in a variety of animal models of inflammatory 
disease, including pleurisy, arthritis, and lung injury [141]. In a 
carrageenan-induced pleurisy model treatment of the animals with 
roscovitine caused a reduction in oedema and reduced concentrations of 
pro-inflammatory cytokines, and caused a reduction in the populations of 
neutrophils, macrophages, and monocytes. Concomitant treatment with 
the apoptosis inhibitor zVAD-fmk ablated these beneficial effects, 
suggesting that the benefits of roscovitine were due to enhanced apoptosis 
of inflammatory cells.  
 
In a bleomycin-induced lung injury model mice treated with roscovitine 
saw a reduction in the number of neutrophils present in fluid from 
bronchial lavage and a reduction in inflammation. Importantly, roscovitine 
led to an increase in survival of the treated animals compared to untreated 
[141]. In vitro roscovitine led to rapid onset of apoptosis in neutrophils, 
effects that were observed even in the presence of potent survival factors, 
such as GM-CSF and LPS [141]. These observations are potentially very 
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interesting, given that efficacy is maintained in spite of the redundancy 
and diversity in the signalling pathways activated by these factors, 
implying perhaps that the anti-inflammatory action is due to an effect of 
roscovitine on a more fundamental cellular function. It has been shown 
recently that inhibition of CDK7 and CDK9 by roscovitine causes loss of 
phosphorylation of the RNA Pol II CTD and affects neutrophil 
transcriptional activity, and is responsible for the induction of apoptosis in 
neutrophils [237]. 
 
Pneumonia remains one of the most common infections in the world with 
around 450 million cases per year, resulting in about 4 million deaths. 
Typically caused by viral or bacterial infections, pneumonia is an 
inflammatory condition causing the alveoli to fill with fluid, reducing 
blood oxygenation levels [238–240].One of the most common causative 
agents is the gram-positive bacteria Streptococcus pneumonia, a 
component of whose cell wall, lipoteichoic acid (LTA), is a major pro-
inflammatory molecule that can induce release of reactive oxygen and 
nitrogen, hydrolases, proteases, growth factors and cytotoxic cytokines 
from neutrophils and macrophages. Roscovitine has been shown in vitro to 
increase apoptosis in polymorphonuclear (PMN) cells and reduce 
secretion of TNF-α and keratinocyte chemoattractant (KC) from alveolar 
macrophage and respiratory epithelial cell lines after exposure to LTA 
[241]. Similarly positive results were observed with roscovitine in an in 
vivo mouse LTS-induced lung inflammation model, where numbers of 
PMN cells in fluid from broncheolavage were reduced, an effect which 
was reversed when apotosis was inhibited [241]. 
 
Fibrosis 
Scleroderma is a chronic autoimmune condition that affects approximately 
240 million individuals worldwide and is characterised by the formation 
of an excess of fibrous connective tissue (fibrosis), either cutaneously or 
systemically, resulting in changes in the vasculature. In a tissue culture 
model roscovitine inhibited the expression of collagen, fibronectin and 
connective tissue growth factor (CTGF) in growth-arrested normal and 
systemic sclerosis (SSc) fibroblasts. This reduction in expression of 
sclerotic proteins was the result of a decrease in transcription of the genes 
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rather than any effect on cell cycle, and was not reversed by treatment 
with the pro-fibrotic cytokines IL-6 or TGF-β [242]. Indeed, in the same 
study the authors also report that roscovitine treatment causes a reduction 
in the secretion of the pro-fibrotic cytokine IL-6. Given the current lack of 
clinical options for treating scleroderma, these observation strengthen any 
case for the testing of roscovitine in a more clinically relevant model. 
 
Stroke 
Ischaemic strokes arise when blood flow to a part of the brain is restricted, 
leading to tissue damage and loss of function in the area affected. 
Neuroprotective therapies are being sought to counter ischaemic injury 
and CDKs (being involved in apoptosis, they are one of the groups of drug 
targets being examined)[243–246]. CDK5 plays a pivotal role in the 
regulation of neuronal cell death and survival; and in pathological 
situation its activity is dysregulated by proteolytic cleavage of its partner 
protein p35 to p25. A CDK5/p25 complex is translocated to the cytoplasm 
and is promiscuous in its activity, compared to CDK5/p35, 
hyperphosphorylating substrates leading to neuronal cell death [11, 247]. 
Cyclin D1, CDK4 and CDK2 upregulation have also been observed during 
neuronal apoptosis and during proliferation of glial cells following 
cerebral ischaemia [248–251]. S-roscovitine has shown neuroprotective 
effects when used in models of ischaemia. The compound crossed the 
blood-brain barrier and showed protective effects (and reduced CDK5/p25 
activity) when dosed after an ischaemic episode, suggesting that the 
compound functions by a mechanism involving CDK5 [252]. 
 
Glaucoma 
Glaucoma is a term used to describe a number of eye disorders caused by 
changes in intraocular pressure. Most commonly associated with increased 
intraocular pressure it can, if left untreated, lead to irreversible retinal 
damage and blindness. Roscovitine has been shown to induce a relaxation 
of the pig trabecular meshwork, a zone around the cornea responsible for 
draining aqueous humour from the eye, suggesting a possible role in the 
control of intraocular pressure (IOP). CDKs have been reported to be 
involved in cellular responses to increased IOP, the cause of retinal cell 
damage. Both R- and S-roscovitine have been tested in vivo in a model of 
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rabbit glaucoma and both have shown beneficial effects in reducing the 
IOP. S-roscovitine was thought by the authors to be of greater potential 
benefit, because in vitro R-roscovitine, in contrast to S-roscovitine, 
amplified the effects of the Endosplasmic Reticular Stress, inducing 
compound tunicamycin, and increased oxygen-glucose deprivation 
induced cell death [253]. 
 
Seizure 
Paroxysmal attacks are brief spasms or seizures often associated with 
other disorders, including multiple sclerosis, encephalitis, head trauma, 
stroke, and epilepsy, amongst others [254]. Attacks can be brought on by a 
wide variety of stimuli, including touch, heat, movement, and exercise. 
They are painful and can cause speech difficulty, lack of coordination, and 
loss of feeling. They resemble epileptic seizures, but lack the abnormal, 
rhythmic discharging of cortical neurons, and can vary enormously in 
frequency, but generally respond well to treatment with drugs, typically 
the anticonvulsant carbamzepine [255]. 
 
γ-aminobutyric acid (GABA) is a mammalian neurotransmitter and is a 
key molecule in controlling neuronal excitability throughout the nervous 
system. It functions primarily at inhibitory synapses in the brain by 
binding to two classes of transmembrane receptors in the plasma 
membrane, leading to hyperpolarisation of the neuron, and causing an 
inhibitory effect on neurotransmission by reducing the possibility of a 
successful action potential. Small molecules with the capacity to alter 
GABA receptor activity have the potential to be of use in the treatment of 
epilepsy and similar neurological conditions. Roscovitine has been shown 
to increase GABA mediated current in rat hippocampal neurons, without 
modifying GABAA receptors. The compound leads to an increase in 
neuronal GABA concentration and suppresses spiking in hippocampal 
pyramidal cells, a characteristic that may ultimately be beneficial in the 
prevention of paroxysmal activity [256], an observation that is worthy of 
further research. 
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Ischaemia-Reperfusion Injury (IR) 
After a period of ischaemia (lack of oxygen) caused by lack of blood flow, 
a tissue can be damaged once oxygenation is reinstated. During or 
following transplant or bypass surgery, stroke or myocardial infaction 
ischaemia can pose serious problems when inflammation and oxidative 
stress can occur [257, 258]. Following previously reported anti-
inflammatory properties,roscovitine has been tested in a rat model of renal 
IR and the authors concluded that treatment of the animals with 
roscovitine before ischaemia resulted in reduced renal damage, as 
measured by a number of blood chemical markers and histopathological 
examination [259]. 
 
In another study Topaloglu and colleagues [260] investigated the effect of 
pre-dosing of roscovitine on IR to the right hepatic lobe and noted that 
roscovitine caused a significant reduction in the number of dead and 
apoptotic cells in the livers, and a reduction in leukocyte infiltration 
consistent with protection from injury and inflammation [260]. 
 
Summary 
As described above roscovitine has been tested pre-clinically in a wide 
variety of disease models and has shown potential therapeutic benefit in 
many. Further research is required in orderto ascertain whether the initial 
signs seen in these model systems are sufficient to warrant the significant 
financial investment to progress roscovitine or, more likely, a closely 
related molecule, along the drug development pathway. Initially 
discovered as a molecule that caused arrest in the cell cycle by blocking 
CDK2 activity, it is worthy of note how many of the potential therapeutic 
applications of the compound take advantage of the effects of roscovitine 
on the transcriptional CDKs. 
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